KATHMANDU — Issuing a new guidelines on Friday, the World Health Organization has said that saturated fats shouldn’t make up more than 10 percent of a person’s diet.
WHO, which is launching the initiative because cardiovascular diseases, said that the new guidelines are part of an attempt to reduce deaths from cardiovascular diseases. Around one-third of all 54.7 million deaths worldwide in 2016 were from cardiovascular diseases as per the reports.
In its first draft guidelines on fat intake, the UN health agency said to avoid piling on the pounds, both adults and children should ensure that no more than 10 percent of their calories come from saturated fat. That type of fat is found butter, milk, meat, eggs and chocolate, among other items.
“Modifiable risk factors such as unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol are major causes of CVDs,” the WHO said in a press release. “Dietary saturated fatty acids and trans-fatty acids are of particular concern as high levels of intake are correlated with increased risk of CVDs.”
WHO said only 1 percent or less of calories should be from transfats, commonly found in baked and fried foods, processed foods and cooking oils.
Before the guidelines are approved, WHO is seeking public comment on them starting Friday, and running through June 1. An external expert group will also provide a peer-review of the guidelines before they are finalized.
In a daily diet of 2,500 calories, 10 percent comes out out to about 25 grams of saturated fat.
Among commonly-eaten foods, 3 ounces of regular ground beef contains 6.1 grams of saturated fat, fried chicken contains 3.3 grams, fried fish contains 2.8 grams, a regular slice of cheese contains 6 grams, 1 cup of 1 percent fat milk contains 4.6 grams and 1 teaspoon of butter contains 2.4 grams.
With Agency InputsFollow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost